- Home
- SGC vs VYGR Comparison
SGC vs VYGR Comparison
Compare SGC & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGC
- VYGR
- Stock Information
- Founded
- SGC 1920
- VYGR 2013
- Country
- SGC United States
- VYGR United States
- Employees
- SGC N/A
- VYGR N/A
- Industry
- SGC Apparel
- VYGR Biotechnology: Pharmaceutical Preparations
- Sector
- SGC Consumer Discretionary
- VYGR Health Care
- Exchange
- SGC Nasdaq
- VYGR Nasdaq
- Market Cap
- SGC 155.7M
- VYGR 172.6M
- IPO Year
- SGC N/A
- VYGR 2015
- Fundamental
- Price
- SGC $10.88
- VYGR $3.31
- Analyst Decision
- SGC Strong Buy
- VYGR Strong Buy
- Analyst Count
- SGC 3
- VYGR 8
- Target Price
- SGC $17.00
- VYGR $14.33
- AVG Volume (30 Days)
- SGC 47.4K
- VYGR 636.1K
- Earning Date
- SGC 08-05-2025
- VYGR 08-05-2025
- Dividend Yield
- SGC 5.10%
- VYGR N/A
- EPS Growth
- SGC N/A
- VYGR N/A
- EPS
- SGC 0.45
- VYGR N/A
- Revenue
- SGC $563,931,000.00
- VYGR $66,958,000.00
- Revenue This Year
- SGC N/A
- VYGR N/A
- Revenue Next Year
- SGC $4.31
- VYGR $78.88
- P/E Ratio
- SGC $24.45
- VYGR N/A
- Revenue Growth
- SGC 2.28
- VYGR N/A
- 52 Week Low
- SGC $9.11
- VYGR $2.65
- 52 Week High
- SGC $20.70
- VYGR $9.55
- Technical
- Relative Strength Index (RSI)
- SGC 53.68
- VYGR 53.13
- Support Level
- SGC $10.46
- VYGR $3.15
- Resistance Level
- SGC $11.58
- VYGR $3.36
- Average True Range (ATR)
- SGC 0.39
- VYGR 0.19
- MACD
- SGC 0.01
- VYGR 0.00
- Stochastic Oscillator
- SGC 37.50
- VYGR 43.06
About SGC Superior Group of Companies Inc.
Superior Group Of Companies Inc designs apparel products. The company's operating segment includes Branded Products; Healthcare Apparel and Contact Centers. It generates maximum revenue from the Branded Products segment. The Branded Products segment produce and sell customized merchandising solutions, promotional products and branded uniform programs to customers.
About VYGR Voyager Therapeutics Inc.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.